OvaScience’s AUGMENT Takes A Pregnant Pause In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech voluntarily suspended a U.S. trial of its IVF-enhancing cell therapy after receiving word from FDA that it needs to follow a different regulatory path.